Syngene International Ltd. · NSE:SYNGENE
Syngene International — Investor Presentation (October 2020)
38 slides from Syngene International's investor presentation, October 2020
Slide 1: Investor Presentation
Investor Presentation October 2020 Strictly confidential and privileged
Slide 2: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 3: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 4: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 5: Positive revenue momentum in second quarter
Positive revenue momentum in second quarter Operating Highlights Financial Highlights • Overall growth for the quarter was driven by good • Q2 revenue from operations up 12% year-on-year traction in Discovery Services and the Dedicated • Q2 EBITDA growth at 6% and EBITDA margins at 32% R&D Centres.
Slide 6: Q2 FY21 Financial Performance
Q2 FY21 Financial Performance All figures in Rs. Mn unless otherwise specified P&L Summary Q2 FY21 Q2 FY20 YoY Change • Revenue from operations increased by 12% and is driven Revenue from operations 5,196 4,646 12% by our ability to operate at normal levels and continued Total Revenue 5,334 4,852 10
Slide 7: Update on COVID-19
Update on COVID-19 Priorities in these uncertain times COVID research projects Safety and wellbeing Client projects • Joined BMS-led global industry consortium to accelerate of our people back on schedule collaborative research in COVID-19 testing. Resilient supply Focus on operating • RT-PCR testin
Slide 8: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 9: Putting science to work: Who we are and what we do
Putting science to work Who we are and what we do ▪ Offering integrated research, development and manufacturing services to take projects from early discovery to commercial supply ▪ Working with clients from around the world to find solutions to their scientific challenges for small and large molecu
Slide 10: Syngene key facts and figures
Syngene key facts and figures All figures are as on March 31, 2020, unless otherwise specified 360+ active clients 8 collaborations 400+ Patents with top 10 pharmaceutical held with clients companies 1.9 Mn sq. ft. 4200+ talented team of 90% employees of World class infrastructure, scientists in 25-
Slide 11: The Syngene advantage
The Syngene advantage Integrated service provider offering end-to-end Flexible and varied business models drug discovery, development and manufacturing To cater to client requirement services on a single platform International accreditations Experienced in successfully managing large OHSAS 18001 Cer
Slide 12: Our experience spans multiple industry segments and partnerships with global leaders
Our experience spans multiple industry segments and partnerships with global leaders across the world Clinical-stage company Leading manufacturer creating novel medicines of high-tech polymer targeting materials G protein-coupled receptors (GPCRs) Germany head Leading China based quartered chemical
Slide 13: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 14: Biocon group and Syngene
Biocon group and Syngene • Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company • Syngene, a subsidiary of Biocon Limited, was established in 1993 as India’s first Contract Research Organization - Company has 25 years plus of unparalleled experience in novel molecu
Slide 15: About us
About us All figures in Rs. Mn unless otherwise specified A Global CRO Quality Focus • Integrated Drug Discovery, Development and • Quality driven organization Manufacturing service provider • Excellent track record of compliance with • Small and Large Molecules, ADCs, global regulators Oligonucleot
Slide 16: Our journey so far
Our journey so far Foundation Globalization and strategic acquisition • Operations started • Expanded into formulations development • Expansion of R&D Lab • Contract with Endo Pharmaceuticals to develop novel anti cancer biological • Granted 100% Export Oriented Unit (EOU) therapeutic molecules stat
Slide 17: Strong track record of growth and profitability
Strong track record of growth and profitability ▪ Growth driven by increase in sales from existing clients and acquisition of new clients ▪ “Engage, expand and extend” strategy to extend client relationship over a longer period of time ▪ Growth in total number of clients ▪ Increase in average revenu
Slide 18: Multiple levers for growth going ahead
Multiple levers for growth going ahead Expand/Extend Existing Clients Capacity Expansion - High service integration - Consistent investment - Dedicated centres model - FTE services, manufacturing, formulation, biologics, stability Engage New Clients - Tailored service offerings and Client Capacity d
Slide 19: Our divisions
Our divisions Discovery Development Manufacturing Dedicated Services Services Services R&D Centres Solution: Conducts early-stage Solution: Encompasses activities Solution: Manufacturing services for Solution: These centres offer research, from target identification from pre-clinical to clinical tri
Slide 20: Our collaboration models
Our collaboration models Dedicated R&D Labs Full-time equivalent (FTE) Fee for service (FFS) Risk-reward • Dedicated scientific resources • Dedicated scientific and support • Flexible, on-demand resources with • Rewards based on clearly defined, selected from partner-specified personnel customized a
Slide 21: Our dedicated R&D centres are an industry leading model
Our dedicated R&D centres are an industry leading model >550 Scientists c.200 Scientists c.170 Scientists 8 Scientists 250,000+ sq. ft. laboratory space 70,000 sq. ft. laboratory space 60,000 sq. ft. laboratory space 3,200 sq. ft. laboratory space Largest R&D Centre in Asia for BMS Dedicated R&D Cen
Slide 22: Our end-to-end platform enables us to be a 'one-stop-shop'
Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small and large molecules) Discovery Development Manufacturing Chemistry Drug Substance Clinical Supplies Drug Product Small Molecules Large Biology Molecules Integrated Drug Substance – HPAPI Dr
Slide 23: Discovery Services: From target to a drug candidate
Discovery Services: From target to a drug candidate Candidate Hit to lead Lead optimisation Development selection Candidate Candidate 5 Lead Selection Development Compounds Exploratory PK, Tox and Developability Assessment 20 Lead In-Vivo DMPK Profiling, Compounds CADD 500 Lead Generation of focused
Slide 24: Development Services
Development Services ▪ Encompass activities across multiple disciplines as a molecule moves from pre- clinical to clinical trials Preclinical Studies ▪ Key activities include: Drug product ▪ Drug substance development (process R&D and optimisation) Drug Dvpt. Substance ▪ Drug product development (pr
Slide 25: Manufacturing Services
Manufacturing Services Small Molecules • State-of-the-art cGMP (Current Good Manufacturing Practices) facility to manufacture new chemical entities (NCEs) • Designed to support multi gram to 100s of kgs/ batch of Intermediates and APIs for clinical trials • New greenfield investments done in Mangalu
Slide 26: Backed by world class state of the art infrastructure
Backed by world class state of the art infrastructure HQ Campus – 90 Acres where most of Syngene’s capabilities are housed today R&D Expansion: Genome Valley, Hyderabad, India commenced operation in Aug 2019 Biologics Expansion: HQ Campus Biologics Manufacturing Plant API Mfg Expansion: Commercial M
Slide 27: Supported by our highly experienced and qualified team of scientists
Supported by our highly experienced and qualified team of scientists ~5,000* 60,000 23*% strong pool of employees hours of training per year female employees vs 15% in FY16 Environment that engages our employees and enables them to grow 4200*+ scientists delivering quality Promoting cross-functional
Slide 28: Led by a globally experienced management team
Led by a globally experienced management team Management team Jonathan Hunt Dr. Mahesh Bhalgat Sibaji Biswas Ashu Tandon Vinita Shrivastava Chief Executive Officer Chief Operating Officer Chief Financial Officer Chief Commercial Officer Chief Human Resources Officer Previous AstraZeneca Sanofi, Amge
Slide 29: Advised by visionary Board of Directors
Advised by visionary Board of Directors Member of he Board Vinita Bali Kiran Mazumdar Shaw Jonathan Hunt Dr. Carl Dcicco Professor Catherine Rosenberg Non-Executive Chairperson Managing Director and Chief Independent Director Non-Executive Director Independent Director Executive officer Chairperson
Slide 30: Committed to sustainability
Committed to sustainability Safety is at the heart of everything we do Committed to environmental protection Accredited with ISO 45001:2018 for its Occupational Health Accredited with ISO 14001:2015 for its effective and Safety (OH&S) measures Environment Management System (EMS) 1000 KL per Reductio
Slide 31: Consistently received industry recognition for our scientific capability
Consistently received industry recognition for our scientific capability and best practices • Bio-Excellence Award 2018 - At Bengaluru • Dynamic Enterprise of the Year 2016 - Tech Summit, Bengaluru • CMO Leadership Award Winner At the 9th Annual Pharmaceutical Leadership • Best Bioprocessing Excelle
Slide 32: Proactively managing risks
Proactively managing risks Mitigation Risk Mitigation • Widening scope of engagement through new service offerings Client retention and • BCP in place to ensure continuity of • Investment in business development growth operations (Technology to aid remote Business continuity due to working, Continuo
Slide 33: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 34: Q2 and H1 FY21 financial highlights
Q2 and H1 FY21 financial highlights All figures in Rs. Mn unless otherwise specified QoQ Particulars Q2 FY21 Q2 FY 20 YoY Change Q1 FY21 H1 FY21 H1 FY20 YoY Change change Revenue from Operations 5,196 4,646 12% 4,216 23% 9,412 8,855 6% Other Income 138 206 (33%) 153 (10%) 291 411 (29%) Total Revenue
Slide 35: FY20 financial highlights
FY20 financial highlights All figures in Rs. Mn unless otherwise specified Particulars FY20 FY19 YoY Change Revenue from operations 20,119 18,256 10% Balance Sheet Highlights Other Income 816 751 9% Total Revenue 20,935 19,007 10% As on 31st March 2020 Material and power costs 5,652 5,726 (1%) Emplo
Slide 36: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 37: Shareholding and Share Information
Shareholding and Share Information Syngene’s Shareholding Pattern* Syngene’s Share Information* NSE Ticker SYNGENE BSE Ticker 539268 1% Promoter & Market Cap (Rs. Mn) 2,21,180 28% Promoter Group % free-float 28.65% Public Free-float market cap (Rs. Mn) 63,368 Share Outstanding (Mn) 400 ESOP Trust 3M
Slide 38: Thank You
THANK YOU For more details www.syngeneintl.com • Visit www.syngeneintl.com • Link to latest FY20 Annual Report • IR Contact: Krishnan G + 91 806 891 9807 investor@syngeneintl.com Putting Science to Work
Syngene International — Investor Presentation (October 2020) on 6ix